Format

Send to

Choose Destination
Expert Opin Biol Ther. 2017 Jun;17(6):747-753. doi: 10.1080/14712598.2017.1304913. Epub 2017 Apr 7.

Daclizumab for the treatment of relapsing-remitting multiple sclerosis.

Author information

1
a Department of Neurology , Klinikum rechts der Isar, Technical University of Munich , Munich , Germany.
2
b Institute of Neuronal Cell Biology , Technical University of Munich , Munich , Germany.
3
c Munich Cluster for Systems Neurology (SyNergy) , Munich , Germany.

Abstract

Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system. Over the last two decades, the number of therapeutic options for the treatment of relapsing remitting MS (RRMS) has been constantly growing, providing new treatment options to patients. Areas covered: Herein, the authors review the recently approved monoclonal antibody daclizumab for the treatment of RRMS. Based on original articles, they discuss its mode of action and evaluate its efficacy and safety profile compared to other available agents. Expert opinion: The IL-2 receptor modulator daclizumab is a new highly effective agent for the treatment of RRMS with novel immunomodulatory properties. Compared to interferon-beta i.m., daclizumab is more effective in reducing relapse rates and MRI activity. However, its use is limited by the risk of autoimmune disorders and hepatotoxicity. Similar to other monoclonal antibodies for RRMS, therapy with daclizumab needs a strict preselection and monitoring of patients based on individual risk benefit assessment. Given its substantial effectiveness, daclizumab can be an attractive option for patients with highly active MS.

KEYWORDS:

Antibody; daclizumab; disability; interleukin-2 receptor; multiple sclerosis; natural killer cells; opinion; therapy

PMID:
28286970
DOI:
10.1080/14712598.2017.1304913
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center